Companies: 10,795·Total market cap: $144.5T

Beam Therapeutics Inc.

Beam Therapeutics Inc.

BEAMNASDAQHealthcare● Active

$29.40

$-3.44(-10.48%)

Market Cap$3.0B

P/E Ratio—

52W High$36.44

52W Low$15.6

Avg Volume2.0M

Open$32.51

Beta2.20

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Beam Therapeutics Inc.（BEAM）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · BEAM · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-0.64Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$164.0MFull revenue history

Dividend Yield4.80%Dividend history

Shares Outstanding98.9MShares outstanding history

Next EarningsAug 4, 2026Est.Earnings history

探索 Beam Therapeutics Inc. 数据

分析师预测$48 · Buy

营收$139.7M+120.01%

盈利EPS $-0.81+82.31%

财务快照

FY 2025Revenue$139.7M▲ +120.01% YoY

202320242025

FY 2025Net Income-$80.0M▲ +78.77% YoY

202320242025

FY 2025EPS$-0.81▲ +82.31% YoY

202320242025

TTM:Revenue: $164.0MNet Income: -$65.0MEPS: $-0.64View income statement →

分析师评级与目标价

Buy27 位分析师

Strong Buy

0

Buy

18

Hold

8

Sell

1

Strong Sell

0

12-Month Price Target

$26.00Low

$29.40Current

$48.00Avg Target上涨空间 63.27%

$80.00High

合计: 27 · 买入占比: 66.7%

根据过去 3 个月内 27 位华尔街分析师，BEAM 共识评级为 Buy，12 个月平均目标价 $48.00 （较现价 $29.40 上涨空间 63.27%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Beam Therapeutics Inc.

$29.40-10.48%$3.0B #2

Agios Pharmaceuticals, Inc.

$28.29-1.74%$1.7B #3

Cogent Biosciences, Inc.

$31.02-5.40%$5.3B #4

Denali Therapeutics Inc.

$19.52-3.08%$3.1B #5

$14.84+0.00%$2.2B #6

$27.98+1.71%$1.8B

股票表现

1D-10.48%

1W+2.40%

1M-9.03%

3M+10.78%

YTD+6.06%

1Y+61.81%

5Y-65.65%

关于 Beam Therapeutics Inc.

CEOJohn Evans

IPO DateFeb 6, 2020

Employees393

CountryUS

Websitebeamtx.com

Beam Therapeutics Inc. a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the trea…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Beam Therapeutics Inc.（BEAM）是 Biotechnology 行业的 Healthcare 类公司，于 Feb 6, 2020 在 NASDAQ 上市。截至最近交易日，BEAM 股价为 $29.40，市值约为 $3.0B。过去12个月累计回报 +61.81%，年初至今回报 +6.06%。

根据 27 位华尔街分析师，Beam Therapeutics Inc. 股票共识评级为Buy，12个月平均目标价为 $48.00。2025 财年 Beam Therapeutics Inc. 营收 $139.7M，净利润 -$80.0M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Beam Therapeutics Inc.（BEAM）股价为 $29.40，在 NASDAQ 上市，52周区间为 $15.60 – $36.44。

BEAM 最新股价BEAM quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议